U.S. Supreme Court declines to hear biologic drug patent fight

WASHINGTON (Reuters) - The U.S. Supreme Court on Monday declined to hear a case over whether companies that make copycat versions of biologic drugs must wait 180 days after winning federal approval before bringing them to the market.